Sebolt-Leopold JS - Search Results

1

MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.

Collins MA, Yan W, Sebolt-Leopold JS, Pasca di Magliano M. Collins MA, et al. Gastroenterology. 2014 Mar;146(3):822-834.e7. doi: 10.1053/j.gastro.2013.11.052. Epub 2013 Dec 6. Gastroenterology. 2014. PMID: 24315826 Free PMC article.

2

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.

Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J. Williams TM, et al. Mol Cancer Ther. 2012 May;11(5):1193-202. doi: 10.1158/1535-7163.MCT-12-0098. Epub 2012 Mar 12. Mol Cancer Ther. 2012. PMID: 22411900 Free PMC article.

3

ERK activation is required for CCK-mediated pancreatic adaptive growth in mice.

Holtz BJ, Lodewyk KB, Sebolt-Leopold JS, Ernst SA, Williams JA. Holtz BJ, et al. Am J Physiol Gastrointest Liver Physiol. 2014 Oct 1;307(7):G700-10. doi: 10.1152/ajpgi.00163.2014. Epub 2014 Aug 7. Am J Physiol Gastrointest Liver Physiol. 2014. PMID: 25104499 Free PMC article.

4

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

Allen LF, Sebolt-Leopold J, Meyer MB. Allen LF, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16. doi: 10.1053/j.seminoncol.2003.08.012. Semin Oncol. 2003. PMID: 14613031 Review.

5

Targeting the mitogen-activated protein kinase cascade to treat cancer.

Sebolt-Leopold JS, Herrera R. Sebolt-Leopold JS, et al. Nat Rev Cancer. 2004 Dec;4(12):937-47. doi: 10.1038/nrc1503. Nat Rev Cancer. 2004. PMID: 15573115 Review.

6

Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.

Van Dort ME, Galbán S, Wang H, Sebolt-Leopold J, Whitehead C, Hong H, Rehemtulla A, Ross BD. Van Dort ME, et al. Bioorg Med Chem. 2015 Apr 1;23(7):1386-94. doi: 10.1016/j.bmc.2015.02.053. Epub 2015 Mar 6. Bioorg Med Chem. 2015. PMID: 25766633 Free PMC article.

7

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.

Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS. Ziemke EK, et al. Clin Cancer Res. 2016 Jan 15;22(2):405-14. doi: 10.1158/1078-0432.CCR-15-0829. Epub 2015 Sep 14. Clin Cancer Res. 2016. PMID: 26369631 Free PMC article.

8

Oncogenic Mutants of MEK1: A Trilogy Unfolds.

Maust JD, Whitehead CE, Sebolt-Leopold JS. Maust JD, et al. Among authors: sebolt leopold js. Cancer Discov. 2018 May;8(5):534-536. doi: 10.1158/2159-8290.CD-18-0192. Cancer Discov. 2018. PMID: 29716939

9

Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.

Maust JD, Frankowski-McGregor CL, Bankhead A 3rd, Simeone DM, Sebolt-Leopold JS. Maust JD, et al. Among authors: sebolt leopold js. Mol Cancer Ther. 2018 Dec;17(12):2495-2506. doi: 10.1158/1535-7163.MCT-18-0082. Epub 2018 Sep 25. Mol Cancer Ther. 2018. PMID: 30254182 Free PMC article.

10

Deciphering the Complexity of MEK Mutations in the Clinic.

Whitehead CE, Sebolt-Leopold JS. Whitehead CE, et al. Among authors: sebolt leopold js. Cancer Res. 2020 Oct 1;80(19):4042-4043. doi: 10.1158/0008-5472.CAN-20-2611. Cancer Res. 2020. PMID: 33008803

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters